Feb 22 |
Athira Pharma GAAP EPS of -$3.09 beats by $0.25
|
Feb 22 |
Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
|
Feb 15 |
2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)
|
Feb 8 |
Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
|
Jan 22 |
With 36% ownership, Athira Pharma, Inc. (NASDAQ:ATHA) has piqued the interest of institutional investors
|
Jan 8 |
Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
|
Jan 3 |
Athira Pharma Completes Enrollment of Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease
|
Jan 2 |
Athira Pharma 10% owner Perceptive Advisors discloses purchase of 605,686 shares
|
Jan 2 |
$1.5M Bet On This Healthcare Stock? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying
|
Dec 26 |
Is Athira Pharma (NASDAQ:ATHA) In A Good Position To Deliver On Growth Plans?
|